Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
Overview
Orthopedia (KIDS) is a specialized medical device company dedicated exclusively to the field of pediatric orthopedics. Operating at the intersection of advanced medical technology and clinical expertise, the company designs, develops, and commercializes anatomically appropriate implants and surgical instruments. These innovative solutions are crafted to meet the distinct needs of pediatric patients, addressing conditions from long bone deformity correction and trauma management to spinal procedures and sports medicine. Keywords such as pediatric orthopedics, surgical implants, and clinical education reinforce the company’s technical focus from the very first introduction.
Core Business and Product Offering
At the heart of Orthopedia's operations lies a commitment to empowering pediatric orthopedic surgeons. The company’s product portfolio encompasses a range of state-of-the-art implants and instruments – each meticulously engineered to provide optimal treatment outcomes. Their offerings include specialized devices that aid in the correction of limb deformities, stabilization of fractures, and support for reconstructions, all designed with the care and precision that pediatric cases demand.
- Dedicated Research and Development: Orthopedia invests in continuous innovation, leveraging cutting-edge technology to refine implant design and improve surgical outcomes.
- Clinical and Educational Support: Beyond product development, the company emphasizes comprehensive clinical education and support programs that help surgeons stay updated on the latest procedures and applications.
- Comprehensive Product Range: From long bone deformity correction to trauma, spine care, and sports medicine, the company offers an integrated suite of solutions tailored for pediatric needs.
Market Position and Industry Significance
Orthopedia has positioned itself as a trusted name within the pediatric orthopedic market. With an unwavering focus on quality and innovation, the company has developed an expertise that ensures its products meet rigorous safety and efficacy standards. Its dedicated approach sets it apart from competitors who cover broader orthopedic applications, as Orthopedia champions solutions specifically designed for children. This clear specialization has cemented its role as a key industry resource for surgeons looking for products that reliably address pediatric orthopaedic conditions.
Operational Excellence and Expertise
The company’s operational framework is built upon a solid foundation of expert knowledge and technical prowess. By integrating engineering innovation with clinical insight, Orthopedia ensures that every implant and instrument is both practical in a surgical environment and tailored for the unique demands of pediatric physiology. The emphasis on quality, reliability, and educational support further demonstrates a commitment to elevating standard practices within the field. This multifaceted approach underlines the company’s role as not only a supplier of medical devices, but also as a partner in advancing pediatric orthopedic care globally.
Customer and Stakeholder Focus
Orthopedia’s offerings are crafted with the end-user in mind, primarily targeting healthcare institutions and pediatric orthopedic surgeons. The company’s comprehensive support system includes detailed training and ongoing clinical education, ensuring that surgeons are capable of utilizing these advanced tools to their fullest potential. Through its balanced approach to innovation and education, Orthopedia helps customers achieve better surgical outcomes and improved quality of life for pediatric patients.
Conclusion
In summary, Orthopedia (KIDS) exemplifies an unwavering focus on the niche field of pediatric orthopedics. The company combines advanced product engineering, dedicated clinical support, and a targeted market strategy to address the specialized needs of pediatric surgical care. By maintaining a consistent emphasis on quality and clinical expertise, Orthopedia continues to serve as a central resource for pediatric orthopedic solutions in the healthcare industry.
OrthoPediatrics Corp. (Nasdaq: KIDS) will participate in a fireside chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021. The session will feature company executives including President Dave Bailey, COO and CFO Fred Hite, and CEO Mark Throdahl. The fireside chat will provide insights into the advancement of pediatric orthopedics, showcasing OrthoPediatrics' commitment to improving children's lives through innovative surgical systems. The event will be available via a webcast at 1:00 PM ET, with a replay available for 90 days.
OrthoPediatrics Corp. (NASDAQ: KIDS) will release its Q1 2021 financial results on May 5, 2021, after the market closes. A conference call to discuss these results is scheduled for May 6, 2021, at 8:00 a.m. ET, with dial-in numbers for domestic and international participants. The company focuses exclusively on pediatric orthopedics, offering a broad range of surgical systems across trauma, scoliosis, and sports medicine. Its products are distributed in the U.S. and 44 other countries.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021. Key executives, including President Dave Bailey and CEO Mark Throdahl, will engage in a fireside chat at 12:45 PM ET. The event is accessible via webcast, and a replay will be available for 90 days. OrthoPediatrics, established in 2006, specializes in pediatric orthopedics and offers 35 surgical systems across various categories, including trauma and deformity management, scoliosis, and sports medicine.
OrthoPediatrics Corp. (Nasdaq: KIDS) has successfully performed over 500 ApiFix procedures for treating progressive adolescent idiopathic scoliosis (AIS), marking significant milestones for its innovative technology. The ApiFix offers a less invasive, motion-preserving option without the permanence of fusion, with a typical surgical procedure lasting under two hours and minimal recovery time. The company continues to gather data to establish a new standard for spinal deformity treatment. The ApiFix system is FDA and CE Mark approved, supported by 46 patents worldwide.
OrthoPediatrics reported full year 2020 revenue of $71.1 million, a 2% decline from 2019, impacted by COVID-19's effect on elective surgeries. Q4 revenue was $18.9 million, down slightly from 2019, with a 26.1% increase in domestic sales, but a 77.7% decline in international sales. The company expects 31-38% revenue growth in 2021, projecting sales of $93-$98 million. Notably, operating expenses rose 59.4% in Q4 due to legal settlements, leading to a net loss of $14.0 million for the quarter and $32.9 million for the year.
OrthoPediatrics Corp. (NASDAQ: KIDS) announced that over 200,000 children with orthopedic conditions have been treated using its products as of March 2021. Founded in 2006, the company focuses exclusively on pediatric orthopedics, providing tailored surgical solutions that address the specific needs of children. OrthoPediatrics offers 35 surgical systems that cater to trauma, scoliosis, and sports medicine procedures. The company's mission remains dedicated to enhancing the quality and variety of treatments available for young patients globally.
OrthoPediatrics Corp. (NASDAQ: KIDS) will release its Q4 and full-year 2020 financial results on March 10, 2021, after market close. The company is ensuring accurate accounting for complex transactions, including the acquisition of ApiFix and the transition to sales agencies in three European markets. A conference call will follow on March 11, 2021, at 8:00 a.m. ET to discuss these results. OrthoPediatrics specializes in pediatric orthopedics and markets 35 surgical systems in the U.S. and 43 other countries.
OrthoPediatrics Corp. (NASDAQ: KIDS) was recognized as one of the 2021 Best Places to Work in Indiana, marking the fifth time the company has received this honor. CEO Mark Throdahl highlighted the significance of this award amidst the COVID-19 pandemic, attributing it to valuable employee feedback. The awards program, managed by the Indiana Chamber of Commerce and Best Companies Group, evaluated companies based on workplace policies and employee surveys, with the latter accounting for 75% of the total score. Final rankings will be revealed at an awards ceremony on May 6, 2021.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched APIFIX.COM, a website dedicated to educating families and healthcare providers about the ApiFix procedure for treating progressive adolescent idiopathic scoliosis (AIS). With a focus on patient empowerment, the new site offers comprehensive information about AIS and the advantages of the ApiFix system, a less invasive alternative to spinal fusion. The company has partnered with 20 U.S. clinical centers for a post-approval study registry to monitor the safety and efficacy of this treatment. ApiFix's innovation is supported by 46 patents worldwide.
OrthoPediatrics Corp. (Nasdaq: KIDS) will participate in a fireside chat at the BTIG Virtual MedTech Conference on February 18, 2021, at 10:00 AM ET. Key executives, including President Dave Bailey and COO Fred Hite, will present insights on the company's advancements in pediatric orthopedics.
Investors can access an audio webcast of the presentation through OrthoPediatrics' investor relations website. The company specializes in pediatric orthopedic products, offering 35 surgical systems across multiple categories.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
What is Orthopedia's core business?
How does Orthopedia differentiate itself from other orthopedic companies?
What types of products does Orthopedia offer?
Who are the primary customers of Orthopedia?
How does Orthopedia support clinical education?
What is the significance of technology and innovation for Orthopedia?
How does Orthopedia ensure product quality?
